Research and amplification,
verifiable line by line.
Each report is anchored to the issuer's certified Vault, signed with Ed25519, and distributed from a Market Fortress account on IBN / GlobeNewswire. The version on Bloomberg is byte-identical to the version on the public verification portal, and the institutional reader can verify both against the underlying Vault snapshot.
OncoVista Therapeutics, Inc. (NASDAQ: ONCO).
Phase 3 trial readout in operational and capital context.
A factual analysis of the November 18 trial readout, the conditional approval pathway, the issuer's funded runway, and the contractual milestones disclosed in the underlying 8-K filing.
The reader does not have to trust the analyst, the issuer, or Market Fortress. They click a link and verify the underlying data themselves.
Vault-anchored, Ed25519-signed, wire-distributed, publicly verifiable on every report.
What we built that the existing options do not have.
Sell-side analysts cannot cover the small-cap layer profitably. Sponsored research is structurally treated as marketing. Independent firms have stayed out of the OTC and micro-cap universe almost entirely. We rebuilt the stack from the data layer up so the institutional reader can verify the substance of every report without trusting the firm.
Verifiable at the data layer.
Each numerical claim cites a specific Vault entry. Each report carries an Ed25519 signature over the canonical payload. The version on Bloomberg is byte-identical to the version on the public verification portal, and tampering with either invalidates the signature.
Distribution from a Market Fortress account.
Releases flow from the MF wire account on IBN / GlobeNewswire rather than from the issuer or its IR firm. The institutional reader sees the report on the same syndication chain as sell-side research, with the source-of-truth attribution staying with the publisher.
Editorial firewall, written into the contract.
The issuer subscribes; the issuer does not edit. The factual-review window is forty-eight hours and is limited to numerical corrections. Every post-distribution correction issues as its own publicly signed addendum on the same wire chain.
Sell-side, sponsored, and MF Research.
The rows are structural differences, not feature toggles.
- Sell-side analyst
- Conflicted by banking
- Sponsored research
- Paid by issuer, no firewall
- MF Research
- Paid by issuer, full editorial firewall + 48hr factual-only review
- Sell-side analyst
- Almost never
- Sponsored research
- Yes
- MF Research
- Yes. Built for the small-cap layer first.
- Sell-side analyst
- No
- Sponsored research
- No
- MF Research
- Every numerical claim cites a Vault entry
- Sell-side analyst
- No
- Sponsored research
- No
- MF Research
- Ed25519 signature over canonical payload
- Sell-side analyst
- No
- Sponsored research
- No
- MF Research
- Anyone can verify hash + signature themselves
- Sell-side analyst
- Bank distributes
- Sponsored research
- Issuer distributes (PR firm)
- MF Research
- MF distributes via IBN / GlobeNewswire
- Sell-side analyst
- Yes
- Sponsored research
- Limited
- MF Research
- Yes. Same wire as institutional research.
- Sell-side analyst
- No (buy/sell/hold)
- Sponsored research
- Optional
- MF Research
- Always. Investment Advisers Act compliant.
- Sell-side analyst
- No
- Sponsored research
- No
- MF Research
- Every correction is its own signed addendum
| Capability | Sell-side analyst | Sponsored research | MF Research |
|---|---|---|---|
| Independent of issuer | Conflicted by banking | Paid by issuer, no firewall | Paid by issuer, full editorial firewall + 48hr factual-only review |
| Covers small / micro / OTC | Almost never | Yes | Yes. Built for the small-cap layer first. |
| Every claim cites raw source | No | No | Every numerical claim cites a Vault entry |
| Cryptographic signature on report | No | No | Ed25519 signature over canonical payload |
| Public verification portal | No | No | Anyone can verify hash + signature themselves |
| Distributed from MF wire account | Bank distributes | Issuer distributes (PR firm) | MF distributes via IBN / GlobeNewswire |
| Bloomberg / Reuters pickup | Yes | Limited | Yes. Same wire as institutional research. |
| Recommendation-free | No (buy/sell/hold) | Optional | Always. Investment Advisers Act compliant. |
| Correction trail public | No | No | Every correction is its own signed addendum |
Six deliverables, every report.
Each release ships with the full integrity stack. There is no IR-blast version of the same report.
A signed report
PDF and HTML. Carries the Ed25519 signature, the canonical Vault snapshot hash, and a verification slug printed on the cover.
Wire distribution
Issued from MF's IBN / GlobeNewswire account. Bloomberg, Reuters, Yahoo Finance, MarketWatch, Benzinga, AP News, and the standard institutional syndication.
A public verification page
A permanent marketfortress.app/research/verify/[slug] URL with the canonical signature, the Vault snapshot hash, the wire receipt, and the byte-identical body.
A 48-hour factual-review window
You flag wrong numbers; we lock the corrected version. No editorial veto. The full review trail is preserved in the audit log.
A built-in correction protocol
If a fact moves post-distribution, the correction issues as its own signed addendum on the same wire chain. Never a silent edit.
An issuer analytics dashboard
Live verification-portal traffic, unique-reader counts, top referrers and countries, and per-report performance vs your prior coverage.
Year-1 rates lock for the duration of continuous subscription. Higher tier rates apply to new sign-ups starting in Year 2, once the platform crosses 100 covered names, the Bloomberg index, and 25 institutional readers. Capped at the first 25 issuers.
Long-form Research and per-event Echo.
Research reports run twenty to forty pages and cover milestone events. Echo amplifications run two hundred to four hundred words and cover everything else that hits the wire.
A single milestone-focused report. FDA approval, customer signing, financing close, restructuring.
Any two reports across the lineup, paired in a single annual engagement.
Quarterly Business Brief plus four Monthly Vault Updates with wire distribution included.
Adds the Industry Context Brief, monthly Material Events Recap, and analyst Q&A access.
Adds Earnings Preview and Post-Mortem coverage, Analyst Day support, and a 24-hour factual-review window.
Deep launch report at the start of any annual relationship. Approximately 25 pages.
Strategic-event deep dive: M&A, restructuring, going-private. Approximately 30 pages.
Multi-issuer industry deep dive distributed under the MF brand to the relevant trade press.
One Echo amplification triggered on any single material event.
Up to ten releases per year, auto-triggered on each material event. Decline any specific release.
Up to twenty-five releases per year. Adds a 30-minute SLA from event detection to wire and priority editorial queue.
Dedicated editor, custom SLA, co-branded distribution. Volume tailored to the issuer.
Per-SKU pricing for Research and Echo coverage lives on the pricing page alongside the platform tiers. Founding-cohort rates lock for the duration of continuous subscription.
The issuer subscribes. The issuer does not control content.
Issuer signs MF Research coverage agreement.
Vault-anchored AI section by section. Each section freezes the snapshot.
MF analyst reviews. Final version signed and locked.
Issuer flags factual errors only. No editorial control.
IBN / GlobeNewswire from MF's wire account. Bloomberg, Reuters, Yahoo Finance.
Public portal hash-checks Vault snapshot + signature + wire receipt.
Founding cohort, capped at the first 25 issuers.
Year-1 rates lock for the duration of continuous subscription. Tier-2 pricing applies to new sign-ups starting in Year 2, once we cross 100 covered issuers, the Bloomberg index, and 25 institutional subscribers. The founding cohort gets the first verifiable research stack at the small-cap layer.